499 related articles for article (PubMed ID: 27841031)
1. Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.
Mota P; Reddy V; Isenberg D
Expert Rev Clin Immunol; 2017 Jul; 13(7):667-676. PubMed ID: 27841031
[TBL] [Abstract][Full Text] [Related]
2. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
3. Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion.
Pérez-Sánchez C; Cecchi I; Barbarroja N; Patiño-Trives AM; Luque-Tévar M; Pérez-Sánchez L; Ibáñez-Costa A; Arias de la Rosa I; Ortega R; Escudero A; Castro MC; Radin M; Roccatello D; Sciascia S; Aguirre MÁ; Collantes E; López-Pedrera C;
J Cell Mol Med; 2019 Sep; 23(9):6308-6318. PubMed ID: 31347786
[TBL] [Abstract][Full Text] [Related]
4. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome.
Coca A; Sanz I
Curr Opin Rheumatol; 2012 Sep; 24(5):451-6. PubMed ID: 22871954
[TBL] [Abstract][Full Text] [Related]
5. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
[TBL] [Abstract][Full Text] [Related]
6. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
7. Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?
Gorman C; Leandro M; Isenberg D
Lupus; 2004; 13(5):312-6. PubMed ID: 15230284
[TBL] [Abstract][Full Text] [Related]
8. Lupus nephritis and B-cell targeting therapy.
Cassia M; Alberici F; Gallieni M; Jayne D
Expert Rev Clin Immunol; 2017 Oct; 13(10):951-962. PubMed ID: 28800401
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
[TBL] [Abstract][Full Text] [Related]
10. Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
Reddy VR; Pepper RJ; Shah K; Cambridge G; Henderson SR; Klein C; Kell L; Taylor SJ; Isenberg DA; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2022 Jul; 61(7):2894-2904. PubMed ID: 34788412
[TBL] [Abstract][Full Text] [Related]
11. Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus.
Jordan N; Lutalo PM; D'Cruz DP
Immunotherapy; 2015; 7(3):255-70. PubMed ID: 25804478
[TBL] [Abstract][Full Text] [Related]
12. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy.
Bela MM; Espinosa G; Cervera R
Lupus; 2021 Jan; 30(1):134-140. PubMed ID: 33081591
[No Abstract] [Full Text] [Related]
13. Successful use of sequential B-cell depletion therapy in lupus.
Psarelis S; Nikiphorou E; Boumpas DT
Lupus; 2018 Feb; 27(2):345-346. PubMed ID: 28639929
[No Abstract] [Full Text] [Related]
14. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
Reddy V; Jayne D; Close D; Isenberg D
Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies.
Fattah Z; Isenberg DA
Expert Opin Biol Ther; 2014 Mar; 14(3):311-26. PubMed ID: 24387632
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
Poh YJ; Baptista B; D'Cruz DP
Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
[TBL] [Abstract][Full Text] [Related]
17. B cell depletion in lupus and Sjögren's syndrome: an update.
Coca A; Sanz I
Curr Opin Rheumatol; 2009 Sep; 21(5):483-8. PubMed ID: 19644378
[TBL] [Abstract][Full Text] [Related]
18. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.
Looney RJ
Drugs; 2010 Mar; 70(5):529-40. PubMed ID: 20297867
[TBL] [Abstract][Full Text] [Related]
19. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
Pers YM; Jorgensen C
Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081
[TBL] [Abstract][Full Text] [Related]
20. Current role of rituximab in systemic lupus erythematosus.
Mok CC
Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
